

# Wei-Ping Zhou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5254289/publications.pdf>

Version: 2024-02-01

59  
papers

6,302  
citations

147801

31  
h-index

133252

59  
g-index

61  
all docs

61  
docs citations

61  
times ranked

9005  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Long Noncoding RNA Activated by TGF- $\beta$ Promotes the Invasion-Metastasis Cascade in Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 666-681.	16.8	1,392
2	METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N <sup>6</sup> -methyladenosine-dependent primary MicroRNA processing. <i>Hepatology</i> , 2017, 65, 529-543.	7.3	685
3	Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, 1214-1227.	3.7	574
4	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). <i>Liver Cancer</i> , 2018, 7, 235-260.	7.7	426
5	Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. <i>Hepatology</i> , 2016, 63, 499-511.	7.3	332
6	Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: A RCT. <i>Journal of Hepatology</i> , 2014, 61, 82-88.	3.7	271
7	The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1. <i>Nature Cell Biology</i> , 2017, 19, 820-832.	10.3	245
8	Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. <i>Nature Communications</i> , 2016, 7, 12992.	12.8	228
9	Antiviral Therapy Improves Postoperative Survival in Patients With Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, 56-66.	4.2	178
10	A Prospective, Randomized, Controlled Trial of Preoperative Transarterial Chemoembolization for Resectable Large Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2009, 249, 195-202.	4.2	177
11	A Noncoding Regulatory RNAs Network Driven by Circ $\beta$ CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 130-147.	7.3	165
12	Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4. <i>Gut</i> , 2015, 64, 156-167.	12.1	115
13	MUC15 Inhibits Dimerization of EGFR and PI3K/AKT Signaling and Is Associated With Aggressive Hepatocellular Carcinomas in Patients. <i>Gastroenterology</i> , 2013, 145, 1436-1448.e12.	1.3	111
14	Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 850-863.	7.3	101
15	Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma. <i>Cancer Letters</i> , 2014, 349, 87-94.	7.2	95
16	Plasma circular RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma: A large-scale, multicenter study. <i>International Journal of Cancer</i> , 2020, 146, 1754-1763.	5.1	83
17	miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. <i>Gut</i> , 2020, 69, 1309-1321.	12.1	78
18	Aldolase B inhibits metastasis through TenEleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2015, 14, 170.	19.2	64

#	ARTICLE	IF	CITATIONS
19	TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling. <i>Scientific Reports</i> , 2016, 6, 37070.	3.3	61
20	Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. <i>Journal of Integrative Medicine</i> , 2018, 16, 236-248.	3.1	61
21	Pioglitazone, a PPAR $\gamma$ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling. <i>Molecular Carcinogenesis</i> , 2015, 54, 1584-1595.	2.7	44
22	HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3. <i>Hepatology</i> , 2021, 74, 1480-1495.	7.3	44
23	Prediction of Hepatocellular Carcinoma Recurrence in Patients With Low Hepatitis B Virus DNA Levels and High Preoperative Hepatitis B Surface Antigen Levels. <i>JAMA Surgery</i> , 2014, 149, 519.	4.3	43
24	Serum miRNAs as predictive and preventive biomarker for pre-clinical hepatocellular carcinoma. <i>Cancer Letters</i> , 2016, 373, 234-240.	7.2	43
25	Hepatitis B virus X protein promotes the stem-like properties of OV6+ cancer cells in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2018, 8, e2560-e2560.	6.3	43
26	CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 18872-18884.	1.8	42
27	Early enforced mobilization after liver resection: A prospective randomized controlled trial. <i>International Journal of Surgery</i> , 2018, 54, 254-258.	2.7	40
28	MicroRNA-197-3p acts as a prognostic marker and inhibits cell invasion in hepatocellular carcinoma. <i>Oncology Letters</i> , 2019, 17, 2317-2327.	1.8	38
29	The histone acetyltransferase hMOF suppresses hepatocellular carcinoma growth. <i>Biochemical and Biophysical Research Communications</i> , 2014, 452, 575-580.	2.1	37
30	Long noncoding RNA, the methylation of genomic elements and their emerging crosstalk in hepatocellular carcinoma. <i>Cancer Letters</i> , 2016, 379, 239-244.	7.2	36
31	miR-515-5p suppresses HCC migration and invasion via targeting IL6/JAK/STAT3 pathway. <i>Surgical Oncology</i> , 2020, 34, 113-120.	1.6	36
32	Early Viral Suppression Predicts Good Postoperative Survivals in Patients with Hepatocellular Carcinoma with a High Baseline HBV-DNA Load. <i>Annals of Surgical Oncology</i> , 2013, 20, 1482-1490.	1.5	35
33	Overactivated neddylation pathway in human hepatocellular carcinoma. <i>Cancer Medicine</i> , 2018, 7, 3363-3372.	2.8	35
34	Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients. <i>Oncotarget</i> , 2017, 8, 28621-28627.	1.8	27
35	Tropomodulin 3 modulates EGFR-PI3K-AKT signaling to drive hepatocellular carcinoma metastasis. <i>Molecular Carcinogenesis</i> , 2019, 58, 1897-1907.	2.7	27
36	Dual regulation of HMGB1 by combined JNK1/2-ATF2 axis with miR-200 family in nonalcoholic steatohepatitis in mice. <i>FASEB Journal</i> , 2018, 32, 2722-2734.	0.5	24

#	ARTICLE	IF	CITATIONS
37	eIF5B increases ASAP1 expression to promote HCC proliferation and invasion. <i>Oncotarget</i> , 2016, 7, 62327-62339.	1.8	24
38	Overexpression of CHKA contributes to tumor progression and metastasis and predicts poor prognosis in colorectal carcinoma. <i>Oncotarget</i> , 2016, 7, 66660-66678.	1.8	23
39	Zinc finger protein X-linked promotes expansion of EpCAM <sup>+</sup> cancer stem-like cells in hepatocellular carcinoma. <i>Molecular Oncology</i> , 2017, 11, 455-469.	4.6	21
40	IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma. <i>Molecular Oncology</i> , 2018, 12, 936-952.	4.6	19
41	Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection. <i>Cancer Medicine</i> , 2020, 9, 2791-2802.	2.8	19
42	Paraoxonase 3 inhibits cell proliferation and serves as a prognostic predictor in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 70045-70057.	1.8	13
43	Co-Upregulation of 14-3-3 $\eta$ and P-Akt is Associated with Oncogenesis and Recurrence of Hepatocellular Carcinoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 1097-1107.	1.6	12
44	Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm: A retrospective cohort study. <i>American Journal of Surgery</i> , 2020, 219, 717-725.	1.8	12
45	Preoperative Hepatitis B Virus DNA Level is a Risk Factor for Postoperative Liver Failure in Patients Who Underwent Partial Hepatectomy for Hepatitis B-Related Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2014, 38, 2370-2376.	1.6	11
46	Opposite regulation of hepatic breast cancer resistance protein in type 1 and 2 diabetes mellitus. <i>European Journal of Pharmacology</i> , 2014, 724, 185-192.	3.5	11
47	Selective Hepatic Vascular Exclusion versus Pringle Maneuver in Partial Hepatectomy for Liver Hemangioma Compressing or Involving the Major Hepatic Veins. <i>American Surgeon</i> , 2014, 80, 236-240.	0.8	10
48	Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy. <i>Surgical Oncology</i> , 2016, 25, 171-177.	1.6	10
49	Hepatocellular carcinoma with inferior vena caval and right atrial tumor thrombi and massive pulmonary artery embolism: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 6, 111-114.	1.0	10
50	Surgery for pregnancy-associated primary hepatocellular carcinoma: Report of four cases. <i>International Journal of Surgery Case Reports</i> , 2014, 5, 882-885.	0.6	9
51	Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1030-1035.	1.6	9
52	Rpb3 promotes hepatocellular carcinoma through its N-terminus. <i>Oncotarget</i> , 2014, 5, 9256-9268.	1.8	8
53	Temporary Ischemia Time Before Snap Freezing Is Important for Maintaining High-Integrity RNA in Hepatocellular Carcinoma Tissues. <i>Biopreservation and Biobanking</i> , 2019, 17, 425-432.	1.0	7
54	Impact of Preoperative Hepatitis B Virus Levels on Prognosis After Primary and Repeat Hepatectomies for Hepatocellular Carcinoma Patients: a Retrospective Study. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 872-883.	1.7	5

#	ARTICLE	IF	CITATIONS
55	Development of preoperative prognostic models including radiological features for survival of singular nodular HCC patients. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, , .	1.3	4
56	Multiple hepatocellular carcinomas: liver resection or transcatheter arterial chemoembolization?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 519-521.	1.5	3
57	Trans-acting non-synonymous variant of FOXA1 predisposes to hepatocellular carcinoma through modulating FOXA1-ER $\alpha$ transcriptional program and may have undergone natural selection. <i>Carcinogenesis</i> , 2020, 41, 146-158.	2.8	3
58	Lamp2 inhibits epithelial-mesenchymal transition by suppressing Snail expression in HCC. <i>Oncotarget</i> , 2018, 9, 30240-30252.	1.8	3
59	Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis. <i>Bioengineered</i> , 2021, , .	3.2	1